



File No. BIO/CT/24/000131

Dated 25-Feb-2025

To,

M/s Klinera Global Services Services,  
801, Neelkanth Corporate Park,  
Opp. Vidyavihar Station Vidyavihar (West)  
Vidyavihar (India) - 400086

Subject: Application for grant of permission to conduct Phase IV clinical trial titled – “A Multicenter, Phase 4, Open-label, Single-arm, Safety Study of Enfortumab Vedotin in Adult Indian Participants with Previously Treated Locally Advanced or Metastatic Urothelial Cancer” vide protocol No. 7465-CL-4001 Amendment No. 01 dated 06.12.2024 - regarding Ref.: Your Application No. BIO/CT04/FF/2024/45915 dated 11-10-2024

Sir,

With reference to your Application No.: BIO/CT04/FF/2024/45915 dated 11-10-2024, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:  
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:  
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVII) The Firm should submit the clinical study report after the completion of the study.

Yours faithfully,

**RAJEEV SINGH**  
**RAGHUVANSHI**

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION,  
2.5.4.20=42d7189b-1c0981bb5a263a4a73d025f4b11b680a91f0  
8773480400a43ee361b, postalCode=110002, st=Delhi,  
serialNumber=657f5e47d940985d8f03bdc902d0e1fe73cfa12a1  
a126ea94a5701124a19013, cn=RAJEEV SINGH RAGHUVANSHI  
Date: 2025.02.28 15:32:56 +05'30'

**FORM CT-06**

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR  
INVESTIGATIONAL NEW DRUG**

The Central Licencing Authority hereby permits M/s Klinera Global Services Services, 801, Neelkanth Corporate Park, Opp. Vidyavihar Station Vidyavihar (West) Vidyavihar (India) - 400086 to conduct clinical trial of the new drug or investigational new drug study titled "A Multicenter, Phase 4, Open-label, Single-arm, Safety Study of Enfortumab Vedotin in Adult Indian Participants with Previously Treated Locally Advanced or Metastatic Urothelial Cancer" vide protocol No. 7465-CL-4001 Amendment No. 01 dated 06.12.2024, in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date: 25-Feb-2025

**RAJEEV SINGH**

**RAGHUVANSHI**

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)  
Central Licencing Authority  
Stamp

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: cn=, o=CENTRAL DRUGS STANDARD CONTROL ORGANISATION,  
ou=CENTRAL DRUGS STANDARD CONTROL ORGANISATION,  
2.5.4.20=42d7189b1c0981bb5a263a4a73d029ff4b11b680a91f087734804  
00a43ee361b, postalCode=110002, st=Delhi,  
serialNumber=6575e47b940985d883bd0c902a0b1fe73cfa12a1a126ea94  
fa5701124a19013, cn=RAJEEV SINGH RAGHUVANSHI  
Date: 2025.02.28 15:34:01 +05'30'

CDSCO

CDSCO

सत्यमेव जयते

MINISTRY OF HEALTH, GOVERNMENT OF INDIA

**Annexure:****Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug:	Enfortumab vedotin 30 mg		
Dosage form:	Powder for concentrate for solution for infusion		
Composition:	Each 30 mg vial contains After reconstitution, each mL of solution contains 10mg of Enfortumab vedotin		
	Ingredient	Function	Composition per 30mg vial
	Enfortumab vedotin IH	Active Pharmaceutical Ingredient	30 mg
	Histidine USP, Ph.Eur., JP	Buffering agent	4.20 mg
	Histidine hydrochloride monohydrate Ph.Eur., J.P.	Buffering agent	6.93 mg
	Trehalose dehydrate NF, Ph.Eur., J.P.	Bulking agent	165 mg
	Polysorbate 20 NF, Ph.Eur., J.P.	Stabilizing agent	0.60 mg
Indications:	The vial is reconstituted with Sterile Water for Injection (SWFI). The reconstituted solution is subsequently diluted in an intravenous infusion bag containing sterile 5% Dextrose Injection, sterile 0.9% Sodium Chloride Injection or Sterile Lactated Ringer's injection Enfortumab vedotin as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor		

**Details of clinical trial site:**

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	Nirmal Hospital Pvt Ltd., Ring Road, Surat-395002, Gujarat, India.	Nirmal Hospital Ethics Committee, Nirmal Hospital Pvt Ltd., Ring Road, Surat-395002, Gujarat, India.  EC Reg. No.: ECR/390/Inst/GJ/2013/RR-19	Dr Anshul Agarwal

2	R.K Birla Cancer Centre, SMS Medical College and Attached Hospital, Department of Medical Oncology & BMT, JLN Marg, Jaipur-302004, Rajasthan, India	Ethics Committee of SMS Medical College & Attached Hospital, Office of Ethics Committee, Second Floor, New Academic Block, S.M.S. Medical College, J.L.N. Marg, Jaipur-302004, Rajasthan, India.  EC Reg. No.: ECR/26/Inst/RJ/2013/RR-19	Dr Sandeep Kumar Jasuja
3	Tata Memorial Centre, Tata Memorial Hospital, Dr Ernest Borges Road, Tata Memorial Hospital, Parel, Mumbai-400012, Maharashtra, India.	Institutional Ethics Committee I/II, Dr Ernest Borges Road, Tata Memorial Centre, Parel, Mumbai-400012, Maharashtra, India  EC Reg. No.: <b>IEC I:</b> EC/NEW/INST/2021/MH/0012 <b>IEC II:</b> EC/NEW/INST/2021/MH/0036	Dr Amit Joshi
4	Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Sundar Bagiya, Near Nariya Gate, Banaras Hindu University Campus, Sunderpur, Varanasi-221005, Uttarpradesh, India.	Institutional Ethics Committee, MPMMCC & HBCH, Varanasi, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Sundar Bagiya, Near Nariya Gate, Banaras Hindu University Campus, Sunderpur, Varanasi-221005, Uttarpradesh, India.  EC Reg. No.: ECR/1501/Inst//UP/2021	Dr Anuj Gupta

CDSCO CDSCO



सत्यमेव जयते

MINISTRY OF HEALTH, GOVERNMENT OF INDIA